ArticleProceedings of the National Academy of Sciences of the United States of America2021
Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis.Systematic reviews · 2026Pooled it
- Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis.JNCI cancer spectrum · 2023Pooled it
- Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis.International journal of colorectal disease · 2022Pooled it
- Diagnostic Accuracy of Blood-Based cfDNA/ctDNA Tests for Colorectal Cancer-A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Earlier postoperative ctDNA detection predicts recurrence and adjuvant therapy benefit in stage II-III colorectal cancer.NPJ precision oncology · 2026Article
- DNA Methylation ofEnvironment & health (Washington, D.C.) · 2026Article
- The interplay between Peptostreptococcus and Fusobacterium as novel signatures in colorectal cancer recurrence.Microbiome · 2026Article
- The Methylation Level of Circulating Tumor DNA Predicts Prognosis for Stage I-III Colorectal Cancer.Journal of gastrointestinal cancer · 2026Article
- Article
- Advancements in DNA methylation technologies and their application in cancer diagnosis.Epigenetics · 2025Review
- Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications.Biomarker research · 2025Review
- Circulating tumor DNA as a biomarker of prognosis prediction in colorectal cancer: a systematic review and meta-analysis.Journal of the National Cancer Center · 2025Article
- Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Whole-genome sequencing of cell-free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas.Molecular oncology · 2025Article
- Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications.Molecular cancer · 2025Review
- Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.MedComm · 2025Review
- The Method of Minimal Residual Disease Detection With Circulating Tumor DNA and Its Clinical Applications in Colorectal Cancer.Cancer reports (Hoboken, N.J.) · 2025Review
- Prognosis in stage II colon cancer: Expanding the horizons of risk factors.World journal of gastrointestinal oncology · 2025Article
- Recurrence Prediction by Multi-Omics in the Patient with Colorectal Peritoneal Metastases After Cytoreductive Surgery: A Prospective Biomarker Study.Cancer management and research · 2025Article
- Methylation ofAdvanced biomedical research · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiplex assays, involving the simultaneous use of multiple circulating tumor DNA (ctDNA) markers, can improve the performance of liquid biopsies so that they are highly predictive of cancer recurrence. We have developed a single-tube methylation-specific quantitative PCR assay (mqMSP) that uses 10 different methylation markers and is capable of quantitative analysis of plasma samples with as little as 0.05% tumor DNA. In a cohort of 179 plasma samples from colorectal cancer (CRC) patients, adenoma patients, and healthy controls, the sensitivity and specificity of the mqMSP assay were 84.9% and 83.3%, respectively. In a head-to-head comparative study, the mqMSP assay also performed better for detecting early-stage (stage I and II) and premalignant polyps than a published SEPT9 assay. In an independent longitudinal cohort of 182 plasma samples (preoperative, postoperative, and follow-up) from 82 CRC patients, the mqMSP assay detected ctDNA in 73 (89.0%) of the preoperative plasma samples. Postoperative detection of ctDNA (within 2 wk of surgery) identified 11 of the 20 recurrence patients and was associated with poorer recurrence-free survival (hazard ratio, 4.20;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.